Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radical Antegrade Modular Pancreatosplenectomy Versus Standard Retrograde Pancreatosplenectomy on the Survival and Prognosis for Resectable Body and Tail Pancreatic Ductal Adenocarcinoma

NCT04253847 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04253847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04253847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radical Antegrade Modular Pancreatosplenectomy Versus Standard Retrograde Pancreatosplenectomy on the Survival and Prognosis for Resectable Body and Tail Pancreatic Ductal Adenocarcinoma
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 15, 2020
Completion date
February 28, 2027
Enrollment
224 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

radical antegrade modular pancreatosplenectomy